Search results
Results from the WOW.Com Content Network
In May 2019, Tonix reported in-licensing the Phase 2 asset, TNX-1300 (T172R/G173Q double-mutant cocaine esterase 200 mg, i.v. solution), for the treatment of cocaine intoxication. [58] [59] TNX-1300 (formerly known as RBP-8000) is being developed under an Investigational New Drug application (IND) for the treatment of cocaine intoxication. [60]
Tianeptine/naloxone (developmental code names TNX-601, TNX-601-CR, TNX-601-ER), or naloxone/tianeptine, is an extended-release combination of tianeptine, an atypical μ-opioid receptor agonist, and naloxone, an orally inactive μ-opioid receptor antagonist, which was under development for the treatment of major depressive disorder, post-traumatic stress disorder (PTSD), and neurocognitive ...
Talizumab (TNX-901) is a humanized monoclonal antibody that was under development by Tanox in Houston, Texas as a new-concept therapeutic for allergic diseases. The unique anti-IgE antibody was designed to target immunoglobulin E and IgE-expressing B lymphocytes specifically, without binding to IgE already bound by the high affinity IgE receptors on mast cells and basophils.
Tenascin-X (TNX) protein was discovered during studies of human steroidogenesis and its disorders, particularly in patients with 21-hydroxylase deficiency, rather than during studies of connective tissue disorders. [32] Researchers sequenced a 2.7 kb cDNA clone that showed similarities to tenascin, leading to the identification of the XB gene. [33]
The Progress-Index is a morning paper, six days a week. It is printed at night, for distribution the following morning. In January 2018, after the closing of the Hopewell News and Mid VA Trading Post by owners Lancaster Media, The Progress-Index launched the twice weekly Hopewell Herald/Prince George Post and weekly classified Mid VA Trader. [4]
The New York Times Index is a printed reference work published since 1913 by The New York Times newspaper. It is intended to serve as a reference for accessing stories printed the previous year in the newspaper. It was created by publisher Adolph Simon Ochs, who wanted to compete with the New York Sun by offering a series of special features ...
Omalizumab, sold under the brand name Xolair among others, is an injectable medication to treat severe persistent allergic forms of asthma, nasal polyps, urticaria (hives), [10] [11] and immunoglobulin E-mediated food allergy.
Name Years NWA X Championship [1]: 2002 NWA–TNA X Championship [1]: 2002 NWA–TNA X Division Championship [2]: 2003 TNA X Division Championship [2]: 2003 – March 1, 2017